
51 - 200 employees
🏥 Healthcare
🧬 Biotechnology
💊 Pharmaceuticals
💰 $96.9M Post-IPO Equity - Rezolute on 2025-04
Healthcare • Biotechnology • Pharmaceuticals
Rezolute, Inc. is a biopharmaceutical company focused on developing and delivering novel therapies for rare metabolic disorders, specifically hyperinsulinism. The company’s lead program, ersodetug, has two Phase 3 programs targeting congenital and tumor hyperinsulinism, and Rezolute conducts clinical trials, investigator-initiated studies, and publishes clinical outcomes. Rezolute also engages with patients, investors, and the medical community to improve care and quality of life for affected patients and families.
Selected: 🆕 Date Added.
🔥 2 hours ago
Senior Medical Science Liaison advancing Rezolute’s rare-disease metabolic and endocrine therapies. Building KOL relationships and supporting scientific exchange, launch readiness, and clinical programs.
🇺🇸 United States – Remote
💵 $200k - $240k / year
💰 $96.9M Post-IPO Equity - Rezolute on 2025-04
⏰ Full Time
🟠 Senior
✨ Medical Science Liaison
👻 Ghost score 0%
🕒 July 27
Head of Global Product Supply for Rezolute leading supply chain and manufacturing transitions. Focus on improving outcomes for rare disease treatments through robust supply chain management.
🏄 California – Remote
💵 $290k - $340k / year
💰 $96.9M Post-IPO Equity - Rezolute on 2025-04
⏰ Full Time
🔴 Lead
👻 Ghost score 6%